SHORT MINI-FUTURE - ELI LILLY & CO | Delayed Deutsche Boerse AG 08:34:47 19/06/2024 pm IST | ||
| 3.92 EUR | -21.60% |
|
| Current month | -56.93% | ||
| 1 month | -67.17% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 19/24/19 | 3.92 | -21.60% |
| 18/24/18 | 5 | +3.95% |
| 17/24/17 | 4.81 | -15.61% |
| 14/24/14 | 5.7 | -1.04% |
| 13/24/13 | 5.76 | -17.83% |
Delayed Quote Deutsche Boerse AG
Last update June 19, 2024 at 08:34 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VD0CE4 |
| ISIN | DE000VD0CE49 |
| Date issued | 14/02/2024 |
| Strike | 938.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 18.5 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 20.01 € |
|---|---|
| Lowest since issue | 3.74 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
891.5
USD
Average target price
855.4
USD
Spread / Average Target
-4.05%
- Stock Market
- Certificates
- Certificat
